About · What We Do
Three practice areas.
One discipline behind all of them.
Growth strategy, channel architecture, and market intelligence. Each addresses a different challenge. The starting point is always the same — a problem that hasn't been fully named yet.
How We Approach the Work
The problem comes first. The method is adapted.
Our methodology adapts to the problem — it never dictates it. The discipline is in resisting the comfortable answer until the harder one has been properly examined.
That discipline carries through to how engagements are staffed. Every engagement is scoped around the actual problem, and the people who start it finish it — no hand-offs after the kickoff, no junior analysts presenting to partners. That is a structural commitment, not something said at the proposal stage.
It also shapes how relationships begin. Most start before there is a formal brief. Half-formed is fine — that is usually the more honest starting point.
Start with the problem, not the product
We do not propose a capability and then find a problem to justify it. The problem comes first. The approach follows.
Senior thinking throughout
The people you meet at the start are the people doing the work. That is a structural commitment, not a pitch.
Honest when we don't know
If the answer isn't clear, we say so. The value is in how we find it — not in performing certainty we don't have.
Small client list by design
We work with a small number of clients at any one time. That is not a constraint — it is how we maintain the quality of the work.
Selected Work
What the work looks like.
Market Entry · US Medical Wearable Device Company · Clinical Trials
A working product. A hypothesis about clinical trials. No clear path to market.
A US-based wearable medical device company believed clinical trials represented a significant growth opportunity but had no view of where to enter, which partners to pursue, or how to build the ecosystem of CROs, pharma companies, and principal investigators needed to get traction. Vaxa mapped the clinical trials landscape, identified the highest-probability entry points, and built the go-to-market strategy and partner ecosystem from the ground up.
A go-to-market strategy and partner ecosystem built from scratch — and a market entry that happened.
Capital · European Radiopharmaceutical Startup · Seed Round · Fundraising
A viable technology. An incomplete investor pipeline. A Series A on the horizon.
A European radiopharmaceutical startup needed to close its seed round, establish a government contract pipeline, and build the financial architecture required to credibly pursue a Series A. Vaxa built the investor network, managed outreach across the European investor community, developed the five-year financial model, and prepared all investor-facing materials — pitch deck, executive summary, and supporting analysis.
Seed round closed. Financial architecture in place for a Series A. Investor pipeline built that didn't exist before the engagement.
Strategic Foundation · Global Medical Device Company · Clinical Trials · Strategy
A new wearable device. An unvalidated market opportunity. A decision that needed to be made.
A global medical device company was evaluating whether to bring a new wearable device into clinical trials. The question was not whether the technology worked — it did. The question was whether the market opportunity justified the investment. Vaxa assessed the opportunity, mapped the clinical trials ecosystem, and built a go-to-market strategy that demonstrated a clear and executable path to market entry.
A validated clinical trials strategy and commercial entry architecture — ready to execute when the organization chose to move.